Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients with melanoma, some other rare skin cancers, and some cancers of the penis and scrotum can have their cancer spread to the lymph nodes in the upper part of the leg, called the groin. Medically, this area is called the inguinal area. At present, for melanomas and skin cancers this type of spread is usually found with a special test called a "sentinel lymph node biopsy". This procedure can find spread of even a few cells in a single lymph node—allowing the treating doctor to find the spread very early.
Treatment for patients with skin cancer in the lymph nodes in this area is to remove all of the lymph nodes in this area. In patients with cancers of the penis and scrotum who do hot have any evidence of cancer having spread either by physical examination or by radiology tests, the lymph nodes in this area are removed to check and see if there is cancer in them. This is called staging.
At present, the standard way to remove all of the lymph nodes in the groin is by a large incision, approximately 8-10 inches in length. For patients who have this operation, there is a very high incidence of infection after surgery: as many as 50% as patients can have a problem after surgery. These infections range from a low grade skin infection needing oral antibiotics to deep infections requiring the wound to be opened and occasionally needing readmission to the hospital and antibiotics given via the vein.
With the advent of new technology and new equipment, the ability to perform this procedure through small incisions away from the groin and further down the leg has become possible. This procedure has never been performed routinely nor compared side by side to the standard open approach. The investigators propose to perform this protocol in two phases.
The investigators have performed procedures in 20 groins to this point and have confirmed the number of lymph nodes and visually verified that the procedure is identical to the open procedure. The investigators performed these procedures in order to insure that the investigators were offering an equivalent option regardless of which procedure the patient is randomized to.
The study will involve the randomization of patients undergoing the procedure. The investigators will randomize the next 110 patients in a 2:1 fashion (two people will get the videoscopic procedure for every one who gets the open procedure) until 73 patients are included in the video arm and 37 in the open arm. Outcomes including recurrence rate, duration of drain requirements, and incidence of lymphedema will be followed. Patients will be followed using standard of care processes, including regular office visits, physical exams, and radiographic imaging, when indicated. Patients will be followed for 5 years.
| Condition | Intervention |
|---|---|
|
Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Penile Carcinoma Urethral Carcinoma Extramammary Paget's Disease Scrotal Carcinoma Anal Cancer Vulvar Cancer Skin Cancer Lymphadenopathy |
Procedure: Videoscopic procedure Procedure: Open, traditional approach |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Videoscopic Versus Open Inguinal Lymphadenectomy for Sentinel Node Positive Cutaneous Malignancies and Genitourinary Staging Procedures |
- Complication profile [ Time Frame: 30 day ] [ Designated as safety issue: Yes ]The primary objective is to assess wound infection, wound dehiscence and other wound complications.
- Length of Stay [ Time Frame: 1- 7 days ] [ Designated as safety issue: No ]Hospital length of stay
- Lymphedema [ Time Frame: 5 years ] [ Designated as safety issue: No ]Assessment of lymphedema will be determined in all patients to identify if there is a difference in all patients undergoing either videoscopic or open inguinal lymphadenectomy
- Nodal Yield [ Time Frame: 5-7 days post procedure ] [ Designated as safety issue: No ]This will characterize, as a surrogate of completeness of surgery, the number of nodes retrieved at the surgical procedure via either approach.
- Readmission [ Time Frame: 30 day ] [ Designated as safety issue: No ]To assess differences in readmission rates between the two groups.
- Oncologic outcomes--survival [ Time Frame: 5 yr ] [ Designated as safety issue: No ]Recurrence free and overall survival will be measured in patients undergoing the procedure to determine if the procedure impacts survival at all.
| Estimated Enrollment: | 110 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | June 2018 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Videoscopic (Minimally invasive)
Patients in this arm will have the procedure done through the three port minimally invasive approach.
|
Procedure: Videoscopic procedure
Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
|
|
Active Comparator: Open (traditional approach)
Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
|
Procedure: Open, traditional approach
Open surgical procedure, with sartorious muscle transfer.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients will be considered for this study if they are between age 18 and 80,
- Have either metastatic melanoma or merkel cell carcinoma diagnosed by sentinel lymph node biopsy or
- Are candidates for a staging procedure for either a penile or scrotal carcinoma, vulvar carcinoma or other cutaneous malignancy.
Exclusion Criteria:
- Patients with unresectable metastatic disease,
- Those who are pregnant or lactating, patients with prohibitive cardiac or pulmonary comorbidities, and
- Patients with other contraindications for general anesthesia as determined by the anesthesia preoperative evaluation will not be considered enrolled in the trial although they may undergo randomization prior to exclusion from surgery.
Contacts and Locations| United States, Georgia | |
| Emory University Hospital-Winship Cancer Institute | Recruiting |
| Atlanta, Georgia, United States, 30322 | |
| Contact: Keith A Delman, MD 404-778-5577 kdelman@emory.edu | |
| Contact: Margi McKellar marjorie.mckellar@emoryhealthcare.org | |
| Principal Investigator: Keith A Delman, MD | |
| Principal Investigator: Viraj Master, MD, PhD | |
| Sub-Investigator: Monica Rizzo, MD | |
| Sub-Investigator: David A Kooby, MD | |
| Sub-Investigator: Kenneth Ogan, MD | |
More Information
Additional Information:
Publications:
| Responsible Party: | Keith A Delman, MD, Associate Professor of Surgery, Emory University |
| ClinicalTrials.gov Identifier: | NCT01526486 History of Changes |
| Other Study ID Numbers: | IRB00012329 |
| Study First Received: | January 28, 2012 |
| Last Updated: | December 16, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Emory University:
|
melanoma urology inguinal lymph nodes groin lymphadenectomy |
groin dissection skin cancer penile cancer urethral cancer scrotal cancer Paget's disease |
Additional relevant MeSH terms:
|
Anus Neoplasms Carcinoma Skin Neoplasms Carcinoma, Merkel Cell Carcinoma, Squamous Cell Melanoma Paget Disease, Extramammary Vulvar Neoplasms Lymphatic Diseases Urethral Neoplasms Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms |
Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Anus Diseases Rectal Diseases Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Skin Diseases Carcinoma, Neuroendocrine Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Adenocarcinoma |
ClinicalTrials.gov processed this record on June 17, 2013